Chitosan reduces plasma adipocytokines and lipid accumulation in liver and adipose tissues and ameliorates insulin resistance in diabetic rats

Journal of Medicinal Food

Volumn 15, Issue 5, 2012, Pages 453-460

  Hsieh, Yu Lin ^a   Yao, Hsien Tsung ^b   Cheng, Ron Shan ^a   Chiang, Meng Tsan ^a  

^a NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

chitosan; chronic inflammation; diabetic rats; fat accumulation; insulin resistance

Indexed keywords

ADIPOCYTOKINE; CHITOSAN; CHOLESTEROL; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INTERLEUKIN 6; NICOTINAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STREPTOZOCIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; LIPID STORAGE; LIPOLYSIS; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; BIOLOGICAL AGENTS; BLOOD GLUCOSE; CHITOSAN; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; LIPID METABOLISM; LIVER; MALE; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 84860442794     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2011.1882     Document Type: Article

References (47)

1. Orban Z, Remaley AT, Sampson M, Trajanoski Z, Chrousos GP: The differential effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and cytokines in man. J Clin Endocrinol Metab 1999;84:2126-2133.
2. Guilherme A, Virbasius JV, Puri V, Czech MP: Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008;9:367-377.
3. Bloomgarden ZT: Adiposity and diabetes. Diabetes Care 2002; 25:2342-2349.
4. Menzaghi C, Trischitta V, Doria A: Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes 2007;56:1198-1209.
5. Guerre-Millo M, Rouault C, Poulain P: PPAR-alpha null mice are protected from high-fat diet-induced insulin resistance. Diabetes 2001;50:2809-2814.
6. Lee CH, Olson P, Evans RM: Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;44:2201-2207.
7. Ide T, Nakazawa T, Mochizuki T, Murakami K: Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats. Metabolism 2000;49:521-525.
8. Guerre-Millo M, Gervois P, Raspe E: Peroxisome proliferatoractivated receptor a activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000;275:16638-16642.
9. Kim H, Haluzik M, Asghar Z: Peroxisome proliferator-activated receptor a agonist treatment in a transgenic model of type 2 diabetes reserves the lipotoxic state and improves glucose homeostasis. Diabetes 2003;52:1770-1778.
10. Kieffer TJ, Habener JF: The glucagon-like peptides. Endocr Rev 1999;20:876-913.
11. Drucker DJ: The biology of incretin hormones. Cell Metab 2006;3:153-165.
12. Toft-Nielsen MB, Damholt MB, Madsbad S: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-3723.
13. Delzenne NM, Cani PD, Daubioul C, Neyrinck AM: Impact of inulin and oligofructose on gastrointestinal peptides. Br J Nutr 2005;93(Suppl 1):S157-S161.
14. Zhou J, Martin RJ, Tulley RT, et al.: Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am J Physiol Endocrinol Metab 2008;295:E1160-E1166.
15. Papathanasopoulos A, Camilleri M: Dietary fiber supplements: effects in obesity and metabolic syndrome and relationship to gastrointestinal functions. Gastroenterology 2010;138:65-72.
16. Shepherd R, Reader S, Falshaw A: Chitosan functional properties. Glycoconj J 1997;14:535-542.
17. Muzzarelli RAA, Ilari P, Petrarulo M: Solubility and structure of N-carboxy-methylchitosan. Int J Biol Macromol 1994;16:177-180.
18. Yao HT, Chiang MT: Effect of chitosan on plasma lipids, hepatic lipids, and fecal bile acid in hamsters. J Food Drug Anal 2006; 14:183-189.
19. Gallaher DD, Gallaher CM, Mahrt GJ, et al.: A glucomannan and chitosan fiber supplement decreases plasma cholesterol and increases cholesterol excretion in overweight normocholesterolemic humans. J Am Coll Nutr 2002;21:428-433.
20. Lee HW, Park YS, Choi JW, et al.: Antidiabetic effects of chitosan oligosaccharides in neonatal streptozotocin-induced noninsulin dependent diabetes mellitus in rats. Biol Pharm Bull 2003;26:1100-1103.
21. Liu SH, Chang YH, Chiang MT: Chitosan reduces gluconeogenesis and increases glucose uptake in skeletal muscle in streptozotocin-induced diabetic rats. J Agric Food Chem 2010; 58:5795-5800.
22. Zhang J, Liu J, Li L, Xia W: Dietary chitosan improves hypercholesterolemia in rats fed high-fat diets. Nutr Res 2008; 28:383-390.
23. Han LK, Kimura Y, Okuda H: Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet. Int J Obes Relat Metab Disord 1999;23:174-179.
24. Sumiyoshi M, Kimura Y: Low molecular weight chitosan inhibits obesity induced by feeding a high-fat diet long-term in mice. J Pharm Pharmacol 2006;58:201-207.
25. Yao HT, Huang SY, Chiang MT: A comparative study on hypoglycemic and hypocholesterolemic effects of high and low molecular weight chitosan in streptozotocin-induced diabetic rats. Food Chem Toxicol 2008;46:1525-1534.
26. Berger JJ, Barnard RJ: Effect of diet on fat cell size and hormone- sensitive lipase activity. J Appl Physiol 1999;87:227-232.
27. Murase T, Yamada N, Matsuzaki F: The in vitro effect of growth hormone on adipose tissue lipoprotein lipase in rats. Life Sci 1981; 28:199-201.
28. Folch J, Lees M, Sloane-Stanley GM: A purification of total lipid from animal tissue. J Biol Chem 1957;226:497-509.
29. Bernstein RL, Hyun WC, Davis JH, et al.: Flow cytometric analysis of mature adipocytes. Cytometry 1989;10:469-474.
30. Maroni BJ, Haesemeyer R, Wilson LK, DiGirolamo M: Electronic determination of size and number in isolated unfixed adipocyte populations. J Lipid Res 1990;31:1703-1709.
31. Hernández-González SO, González-Ortiz M, Martínez-Abundis E, et al.: Chitosan improves insulin sensitivity as determined by the euglycemic-hyperinsulinemic clamp technique in obese subjects. Nutr Res 2010;30:392-395.
32. Matsuzawa Y: The metabolic syndrome and adipocytokines. FEBS Lett 2006;580:2917-2921.
33. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesitylinked insulin resistance. Science 1993;259:87-91.
34. Bastard JP, Maachi M, Van-Nhieu JT, et al.: Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2002;87:2084-2089.
35. Neyrinck AM, Bindels LB, De Backer F, et al.: Dietary supplementation with chitosan derived from mushrooms changes adipocytokine profile in diet-induced obese mice, a phenomenon linked to its lipid-lowering action. Int Immunopharmacol 2009; 9:767-773.
36. Sugano M, Fujikawa T, Hiratsuji Y, Nakashima K, Fukuda N, Hasegawa Y: A novel use of chitosan as a hypocholesterolemic agent in rats. Am J Clin Nutr 1980;33:787-793.
37. Sumiyoshi M, Kimura Y: Low molecular weight chitosan inhibits obesity induced by feeding a high-fat diet long-term in mice. J Pharm Pharmacol 2006;58:201-207.
38. Gallaher CM, Munion J, Hesslink R Jr, Wise J, et al.: Cholesterol reduction by glucomannan and chitosan is mediated by changes in cholesterol absorption and bile acid and fat excretion in rats. J Nutr 2000;11:2753-2759.
39. Yao HT, Chiang MT: Effect of chitosan on plasma lipids, hepatic lipids, and fecal bile acid in hamsters. J Food Drug Anal 2006; 14:183-189.
40. Gutzwiller JP, Drewe J, Goke B, et al.: Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999;276:R1541-R1544.
41. Van-Dijk G, Thiele TE: Glucagon-like peptide-1 (7-36) amide: a central regulator of satiety and interoceptive stress. Neuropeptides 1999;33:406-414.
42. Okuda H, Morimoto C, Tsujita T: Effect of substrates on the cyclic AMP-dependent lipolytic reaction of hormone-sensitive lipase. J Lipid Res 1994;35:1267-1273.
43. Yaney GC, Civelek VN, Richard AM, et al.: Glucagon-like peptide 1 stimulates lipolysis in clonal pancreatic b-cells (HIT). Diabetes 2001;50:56-62.
44. Zechner R: The tissue-specific expression of lipoprotein lipase: implications for energy and lipoprotein metabolism. Curr Opin Lipidol 1997;8:77-88.
45. Zechner R, Strauss J, Frank S, et al.: The role of lipoprotein lipase in adipose tissue development and metabolism. Int J Obes Relat Metab Disord 2000;24(Suppl 4):S53-S56.
46. Lee YS, Shin S, Shigihara T, et al.: Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 2007;56:1671-1679.
47. Matsuo K, Arai H, Muto K, et al.: The anti-obesity effect of the palatinose-based formula inslow is likely due to an increase in the hepatic PPAR-alpha and adipocyte PPAR-gamma gene expressions. J Clin Biochem Nutr 2007;40:234-241.